FOR IMMEDIATE RELEASE


NATUROL'S EXTRACTION TECHNOLOGY YIELDS UNIQUE PACLITAXEL FROM YEW TREES, THE
PRINCIPAL SOURCE OF A MAJOR ANTI CANCER DRUG. Technology could enable Naturol
to deliver high concentrate Taxanes to $1.6 billion cancer chemotherapy drug
market.

June 25TH,ay 23rd, 2002, Las Vegas, Nevada - Coronado Explorations Ltd. (The
Company) (OTC:BB-COOX) announced today that its wholly owned subsidiary
Naturol Inc.'s (www.Naturol.net)  development partner, the Prince Edward
Island Food Technology Centre  ("FTC") (www.gov.pe.ca/ftc) has successfully
recovered high concentrations of Paclitaxel from Canadian Yew using Naturol's
proprietary extraction technology.  A provisional patent application has been
filed to protect the unique extraction process which Naturol intends to use
to produce and further purify Paclitaxel and other Taxane extracts recovered
from Yew trees in Eastern Canada. Naturol Inc. An important aspect of this
new technology , is its ability to produce new and and unique compositions of
oils and protein isolates. is a wholly owned subsidiary of  Coronado,  and
has been granted the exclusive North American license by Naturol U.K. Limited
to develop and commercialise  all the Naturol's extraction technologies.

Global sales of Paclitaxel in 2000 were estimated at $1.6 billion. The
primary U.S. pharmaceutical containing Paclitaxel is TAXOL made by Bristol
Myers Squibb. U.S. based generic manufacturers of Paclitaxel with FDA
approval include Ivax, NaPro and Mylan.

Paclitaxel is recognised as one of the most important cancer chemotherapy
drugs available. It is also one of the few major drugs that cannot be
commercially synthesized  and has to be extracted from natural sources.
Naturol's breakthrough technology is likely to beneficially change the
economics and methods of extracting Paclitaxel and other Taxanes from Yew
trees - the world's most important source of  these bio active compounds.

Paclitaxel presently has US FDA approval for use in treating breast and
ovarian cancer, certain types of lung cancer and is a second line treatment
for AIDS associated with Karposi Sarcoma. Many oncologists believe that
Paclitaxel is also beneficial in treating other cancers not presently on the
FDA approved list. Paclitaxel, along with other taxanes is recovered from the
bark, needles, wood and roots of taxus plants commonly known as  Yew. The Yew
trees in Eastern Canada are unique in that they contain two to three times
the world average concentration of Paclitaxel and other Taxanes and are an
abundant resource and  sustainably harvested.

It has been discovered that the Naturol extraction technology may be uniquely
suited to the recovery of Paclitaxel, and other important Taxanes from the
Canadian Yew.  Because the Naturol process does not require the elevated
temperatures conventionally used in drying Yew cuttings, (believed to destroy
a significant portion of the Taxanes present in the fresh cut Yew needles and
branches), enhanced recovery of Paclitaxel is anticipated.



By using the Naturol extraction technology, the FTC has demonstrated the
ability to produce extracts with a high concentration of Paclitaxel. The FTC
and Naturol technical  teams believe that through their ongoing development
effort they will be able to increase this Paclitaxel concentration to at
least a 30% level. These will be sold to FDA approved companies for further
concentration and purification to 99.9% bulk Paclitaxel, then converted to
pharmaceutical grade products.

Starting early 2003, Naturol plans to process 10 million pounds per year of
freshly harvested Yew from five sites in Eastern Canada and recover
Paclitaxel and other Taxanes in commercially acceptable concentrations.
During 2003, Naturol projects revenues of as much as $9 million from the
recovery of Paclitaxel and other Taxanes from Canadian Yew.

Naturol Inc is dedicated to becoming a global leader in the commercialization
of technology for the production of low cost, high quality extracts from
natural materials. Naturol's proprietary technologies offer a more benign and
cost effective alternative to current extraction technologies  for the
production of quality extracts  for use in the $2.4 billion dollar U.S.
market for plant based pharmaceuticals, nutraceuticals, food additives,
flavors and fragrances.

Forward Looking Statements. The statements in this press release, are forward
looking statements. Such statements involve risks and uncertainties,
including, but not limited to, costs and difficulties related to costs,
delays, and any other difficulties, risks and effects of legal and
administrative proceedings and governmental regulation, future financial and
operational results, competition, general economic conditions and the ability
to manage and continue growth. Should one or more of these risks or
uncertainties materialise, or should underlying assumptions prove incorrect,
actual outcomes may vary materially from those indicated. We undertake no
obligation to revise or update such statements to reflect current events or
circumstances after the date hereo or to reflect the occurrence of
unanticipated events.

CONTACT:
Naturol Inc.
Isaac Moss
Tel: 702 450 1600
Fax: 702 450 5790